Drug Profile
GW 468816
Alternative Names: 468816; GW-468816Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; National Institute of Drug Abuse
- Class Antimigraines; Smoking cessation therapies
- Mechanism of Action Glycine antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Smoking withdrawal
- Discontinued Migraine
Most Recent Events
- 10 Dec 2009 Efficacy data from three clinical trials presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
- 11 Jan 2008 Phase II development is ongoing
- 30 Apr 2002 Discontinued - Phase-I for Migraine in USA (PO)